ZA202309153B - Heterocyclic compounds and uses thereof - Google Patents
Heterocyclic compounds and uses thereofInfo
- Publication number
- ZA202309153B ZA202309153B ZA2023/09153A ZA202309153A ZA202309153B ZA 202309153 B ZA202309153 B ZA 202309153B ZA 2023/09153 A ZA2023/09153 A ZA 2023/09153A ZA 202309153 A ZA202309153 A ZA 202309153A ZA 202309153 B ZA202309153 B ZA 202309153B
- Authority
- ZA
- South Africa
- Prior art keywords
- compounds
- heterocyclic compounds
- pah
- nih
- diabetes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163178309P | 2021-04-22 | 2021-04-22 | |
| PCT/US2022/026059 WO2022226383A1 (en) | 2021-04-22 | 2022-04-22 | Heterocyclic compounds and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202309153B true ZA202309153B (en) | 2025-04-30 |
Family
ID=83723210
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2023/09153A ZA202309153B (en) | 2021-04-22 | 2023-09-28 | Heterocyclic compounds and uses thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12054475B2 (https=) |
| EP (1) | EP4326696A4 (https=) |
| JP (2) | JP7781391B2 (https=) |
| KR (2) | KR20260022493A (https=) |
| CN (1) | CN117897370A (https=) |
| AU (1) | AU2022262654A1 (https=) |
| CA (1) | CA3213692A1 (https=) |
| IL (2) | IL324964A (https=) |
| MX (1) | MX2023012435A (https=) |
| WO (1) | WO2022226383A1 (https=) |
| ZA (1) | ZA202309153B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112638881B (zh) | 2018-07-31 | 2025-01-07 | 普林斯顿大学托管委员会 | 用于治疗转移性和化疗耐受性癌症的四氢喹啉衍生物 |
| WO2021151062A1 (en) * | 2020-01-24 | 2021-07-29 | The Trustees Of Princeton Univeristy | Heterocyclic compounds and uses thereof |
| IL324964A (en) | 2021-04-22 | 2026-01-01 | Kayothera Inc | Modified heterocycles as aldehyde dehydrogenase inhibitors |
| CN116120316B (zh) * | 2022-12-29 | 2025-12-05 | 渭南瑞联制药有限责任公司 | 一种氮杂三环抗菌化合物的合成方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60126270A (ja) | 1983-12-14 | 1985-07-05 | Otsuka Pharmaceut Co Ltd | カルボスチリル誘導体 |
| JPS61145162A (ja) | 1984-12-19 | 1986-07-02 | Otsuka Pharmaceut Co Ltd | カルボスチリル誘導体 |
| DE3701277A1 (de) * | 1987-01-17 | 1988-07-28 | Boehringer Mannheim Gmbh | Neue tricyclische benzimidazole, verfahren zu ihrer herstellung und verwendung als arzneimittel |
| JPH01319453A (ja) | 1988-06-22 | 1989-12-25 | Wakamoto Pharmaceut Co Ltd | 新規ベンゾキノン誘導体 |
| ATE355273T1 (de) | 2003-05-12 | 2006-03-15 | Pfizer Prod Inc | Benzamidinhibitoren des p2x7-rezeptors |
| US20050209247A1 (en) | 2003-11-07 | 2005-09-22 | Chiron Corporation | Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties |
| EP1718306A2 (en) | 2004-02-20 | 2006-11-08 | Chiron Corporation | Modulation of inflammatory and metastatic processes |
| JPWO2006132295A1 (ja) | 2005-06-09 | 2009-01-08 | 大日本住友製薬株式会社 | アルドステロン受容体調節剤 |
| JP2006349902A (ja) | 2005-06-15 | 2006-12-28 | Fujifilm Holdings Corp | 黒白熱現像感光材料 |
| WO2010102286A2 (en) | 2009-03-06 | 2010-09-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Proteasome inhibitors having chymotrypsin-like activity |
| US8541404B2 (en) * | 2009-11-09 | 2013-09-24 | Elexopharm Gmbh | Inhibitors of the human aldosterone synthase CYP11B2 |
| WO2013066469A2 (en) | 2011-08-15 | 2013-05-10 | Seattle Children's Research Institute | Kinase inhibitors capable of increasing the sensitivity of bacterial pathogens to b-lactam antibiotics |
| WO2013027168A1 (en) | 2011-08-22 | 2013-02-28 | Pfizer Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
| WO2013170072A2 (en) * | 2012-05-09 | 2013-11-14 | Neurop, Inc. | Compounds for the treatment of neurological disorders |
| CA2926250A1 (en) | 2013-10-04 | 2015-04-09 | Bayer Cropscience Aktiengesellschaft | Use of substituted dihydro-oxindolyl sulfonamides, or the salts thereof, for increasing the stress tolerance of plants |
| WO2015092118A1 (en) | 2013-12-17 | 2015-06-25 | Orion Corporation | Spiro[cyclobutane-1,3'-indolin]-2'-one derivatives as bromodomain inhibitors |
| HUE051255T2 (hu) | 2014-02-19 | 2021-03-01 | Aviv Therapeutics Inc | Mitokondriális aldehid dehidrogenáz 2 (ALDH2) kötõ policiklusos amidok és alkalmazásuk rák kezelésére |
| EP3143009B1 (en) | 2014-05-12 | 2019-09-18 | Fondazione Istituto Italiano di Tecnologia | Substituted benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments |
| JP6759514B2 (ja) | 2014-08-01 | 2020-09-23 | ヌエヴォリューション・アクティーゼルスカブＮｕｅｖｏｌｕｔｉｏｎ Ａ／Ｓ | ブロモドメインに対して活性な化合物 |
| WO2018109650A1 (en) | 2016-12-14 | 2018-06-21 | Aurigene Discovery Technologies Limited | Spiro[cyclopentane-1,3'-indolin]-2'-one derivatives as bromodomain inhibitors |
| CN108690043B (zh) | 2017-04-11 | 2019-10-18 | 东莞东阳光科研发有限公司 | 喹啉类衍生物及其制备方法和用途 |
| CN112638881B (zh) | 2018-07-31 | 2025-01-07 | 普林斯顿大学托管委员会 | 用于治疗转移性和化疗耐受性癌症的四氢喹啉衍生物 |
| WO2021151062A1 (en) | 2020-01-24 | 2021-07-29 | The Trustees Of Princeton Univeristy | Heterocyclic compounds and uses thereof |
| GB202019475D0 (en) | 2020-12-10 | 2021-01-27 | Cancer Research Tech Ltd | Therapeutic compounds and their use |
| IL324964A (en) | 2021-04-22 | 2026-01-01 | Kayothera Inc | Modified heterocycles as aldehyde dehydrogenase inhibitors |
-
2022
- 2022-04-22 IL IL324964A patent/IL324964A/en unknown
- 2022-04-22 CA CA3213692A patent/CA3213692A1/en active Pending
- 2022-04-22 KR KR1020267003731A patent/KR20260022493A/ko active Pending
- 2022-04-22 AU AU2022262654A patent/AU2022262654A1/en active Pending
- 2022-04-22 CN CN202280042077.8A patent/CN117897370A/zh active Pending
- 2022-04-22 KR KR1020237039718A patent/KR102925139B1/ko active Active
- 2022-04-22 JP JP2023565154A patent/JP7781391B2/ja active Active
- 2022-04-22 IL IL307873A patent/IL307873B1/en unknown
- 2022-04-22 EP EP22792627.6A patent/EP4326696A4/en active Pending
- 2022-04-22 MX MX2023012435A patent/MX2023012435A/es unknown
- 2022-04-22 WO PCT/US2022/026059 patent/WO2022226383A1/en not_active Ceased
-
2023
- 2023-09-28 ZA ZA2023/09153A patent/ZA202309153B/en unknown
- 2023-10-17 US US18/488,924 patent/US12054475B2/en active Active
-
2024
- 2024-06-18 US US18/746,835 patent/US20240343709A1/en active Pending
-
2025
- 2025-11-17 JP JP2025196737A patent/JP2026020230A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL307873A (en) | 2023-12-01 |
| AU2022262654A1 (en) | 2023-10-19 |
| JP7781391B2 (ja) | 2025-12-08 |
| EP4326696A1 (en) | 2024-02-28 |
| MX2023012435A (es) | 2024-02-08 |
| KR20230173703A (ko) | 2023-12-27 |
| WO2022226383A1 (en) | 2022-10-27 |
| KR102925139B1 (ko) | 2026-02-10 |
| US20240132469A1 (en) | 2024-04-25 |
| JP2026020230A (ja) | 2026-02-06 |
| CN117897370A (zh) | 2024-04-16 |
| EP4326696A4 (en) | 2025-06-25 |
| IL307873B1 (en) | 2026-01-01 |
| JP2024514709A (ja) | 2024-04-02 |
| US20240343709A1 (en) | 2024-10-17 |
| IL324964A (en) | 2026-01-01 |
| US12054475B2 (en) | 2024-08-06 |
| CA3213692A1 (en) | 2022-10-27 |
| KR20260022493A (ko) | 2026-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202309153B (en) | Heterocyclic compounds and uses thereof | |
| UA85593C2 (uk) | Похідні хіназолінону як інгібітори parp | |
| NO20061244L (no) | Solvdihydrogencitrat sammensetninger omfattende et andre antimikrobielt middel | |
| MX2024002332A (es) | Derivado heterociclico inhibidor que contiene nitrogeno, y metodo de preparacion y su uso. | |
| SG154432A1 (en) | Quinazolinedione derivatives as parp inhibitors | |
| NO20081952L (no) | Substituerte pyrazolforbindelser | |
| PL406680A1 (pl) | Inhibitory kinaz tyrozynowych | |
| GEP20125702B (en) | Benzimidazole derivatives | |
| CY1106989T1 (el) | Ενεργοποιητες γλυκοκινασης τυπου 5-υποκατεστημενης πυραζινης ή πυριδινης | |
| MY153727A (en) | Pyridazinone derivatives | |
| NZ608667A (en) | N-(3-amino-quinoxalin-2-yl)-sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors | |
| CY1114095T1 (el) | Μυκητοκτονες συνθεσεις | |
| MX2007003104A (es) | Nuevos derivados de ftalazinona, como inhibidores de cinasa aurora-a. | |
| MY143599A (en) | Pyrazole derivatives, compositions containing such compounds and methods of use | |
| UA93351C2 (uk) | Похідні фталазіну як інгібітори parp | |
| NO20051427L (no) | Fremgangsmate for produksjon av hydroksyalkyl stivelsesderivater | |
| MX2009008506A (es) | Derivados del pirazol como inhibidores de 11-b-hsd1. | |
| TW200730174A (en) | Chemical compounds | |
| TW200628471A (en) | Process for the manufacture of fused piperazin-2-one derivatives | |
| BRPI0409276A (pt) | derivados de piperazina inibidores de renina | |
| ATE355265T1 (de) | Biphenylcarboxamidderivate und ihre verwendung als p38 kinase inhibitoren | |
| DE69940320D1 (de) | Betulinsäurederivate zur inhibierung des krebswach | |
| NO20081292L (no) | Pentasykliske kinaseinhibitorer | |
| MX2025004213A (es) | Agentes quimioterapeuticos de eteres macrociclicos heteroaromaticos | |
| ATE269700T1 (de) | Verwendung von docetaxel für die behandlung von hepatozelluläre krebs |